Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women

Tony K.H. Chung, Tak Hong Cheung, So Fan Yim, Mei Yun Yu, Rossa W.K. Chiu, Keith W.K. Lo, Ida P.C. Lee, Raymond R.Y. Wong, Kitty K.M. Lau, Vivian W. Wang, Michael J. Worley, Kevin M. Elias, Stephen J. Fiascone, David I Smith, Ross S. Berkowitz, Yick Fu Wong

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction Cervical cancer is the fourth most common female cancer worldwide. The prognosis for women with advanced-stage or recurrent cervical cancer remains poor and response to treatment is variable. Standardized management protocols leave little room for individualization. We report on a novel blood-based liquid biopsy for specific PIK3CA mutations as a clinically useful biomarker in patients with invasive cervical cancer. Methods One hundred seventeen Hong Kong Chinese women with primary invasive cervical cancer and their pre-treatment plasma samples were investigated. Two PIK3CA mutations, p.E542K and p.E545K were measured in cell free DNA (cfDNA) extracted from plasma using droplet digital PCR. This liquid biopsy of PIK3CA in cervical cancer was correlated to clinico-pathological features to verify the potential of PIK3CA as a clinically useful molecular biomarker for predicting disease prognosis and monitoring for progression. Results PIK3CA mutations, either p.E542K or p.E545K, were detected in plasma cfDNA from 22.2% of the patients. PIK3CA mutation status was significantly correlated to median tumor size (p < 0.01). PIK3CA mutations detected in the plasma were significantly associated with decreased disease-free survival and overall survival (p < 0.05). Conclusions As a liquid molecular biopsy, analysis of circulating PIK3CA mutations shows promise as a way to refine risk stratification of individual patients with cervical cancer, and provides a platform for further research to offer individualized therapy with the purpose of improving outcomes.

Original languageEnglish (US)
Pages (from-to)334-339
Number of pages6
JournalGynecologic Oncology
Volume146
Issue number2
DOIs
StatePublished - Aug 1 2017

Fingerprint

Hong Kong
Uterine Cervical Neoplasms
Biopsy
Mutation
Biomarkers
DNA
Plasma Cells
Disease-Free Survival
Neoplasms
Therapeutics
Polymerase Chain Reaction
Survival
Research

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Chung, T. K. H., Cheung, T. H., Yim, S. F., Yu, M. Y., Chiu, R. W. K., Lo, K. W. K., ... Wong, Y. F. (2017). Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. Gynecologic Oncology, 146(2), 334-339. https://doi.org/10.1016/j.ygyno.2017.05.038

Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. / Chung, Tony K.H.; Cheung, Tak Hong; Yim, So Fan; Yu, Mei Yun; Chiu, Rossa W.K.; Lo, Keith W.K.; Lee, Ida P.C.; Wong, Raymond R.Y.; Lau, Kitty K.M.; Wang, Vivian W.; Worley, Michael J.; Elias, Kevin M.; Fiascone, Stephen J.; Smith, David I; Berkowitz, Ross S.; Wong, Yick Fu.

In: Gynecologic Oncology, Vol. 146, No. 2, 01.08.2017, p. 334-339.

Research output: Contribution to journalArticle

Chung, TKH, Cheung, TH, Yim, SF, Yu, MY, Chiu, RWK, Lo, KWK, Lee, IPC, Wong, RRY, Lau, KKM, Wang, VW, Worley, MJ, Elias, KM, Fiascone, SJ, Smith, DI, Berkowitz, RS & Wong, YF 2017, 'Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women', Gynecologic Oncology, vol. 146, no. 2, pp. 334-339. https://doi.org/10.1016/j.ygyno.2017.05.038
Chung, Tony K.H. ; Cheung, Tak Hong ; Yim, So Fan ; Yu, Mei Yun ; Chiu, Rossa W.K. ; Lo, Keith W.K. ; Lee, Ida P.C. ; Wong, Raymond R.Y. ; Lau, Kitty K.M. ; Wang, Vivian W. ; Worley, Michael J. ; Elias, Kevin M. ; Fiascone, Stephen J. ; Smith, David I ; Berkowitz, Ross S. ; Wong, Yick Fu. / Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. In: Gynecologic Oncology. 2017 ; Vol. 146, No. 2. pp. 334-339.
@article{4de7a67be4d249c9973021679b483941,
title = "Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women",
abstract = "Introduction Cervical cancer is the fourth most common female cancer worldwide. The prognosis for women with advanced-stage or recurrent cervical cancer remains poor and response to treatment is variable. Standardized management protocols leave little room for individualization. We report on a novel blood-based liquid biopsy for specific PIK3CA mutations as a clinically useful biomarker in patients with invasive cervical cancer. Methods One hundred seventeen Hong Kong Chinese women with primary invasive cervical cancer and their pre-treatment plasma samples were investigated. Two PIK3CA mutations, p.E542K and p.E545K were measured in cell free DNA (cfDNA) extracted from plasma using droplet digital PCR. This liquid biopsy of PIK3CA in cervical cancer was correlated to clinico-pathological features to verify the potential of PIK3CA as a clinically useful molecular biomarker for predicting disease prognosis and monitoring for progression. Results PIK3CA mutations, either p.E542K or p.E545K, were detected in plasma cfDNA from 22.2{\%} of the patients. PIK3CA mutation status was significantly correlated to median tumor size (p < 0.01). PIK3CA mutations detected in the plasma were significantly associated with decreased disease-free survival and overall survival (p < 0.05). Conclusions As a liquid molecular biopsy, analysis of circulating PIK3CA mutations shows promise as a way to refine risk stratification of individual patients with cervical cancer, and provides a platform for further research to offer individualized therapy with the purpose of improving outcomes.",
author = "Chung, {Tony K.H.} and Cheung, {Tak Hong} and Yim, {So Fan} and Yu, {Mei Yun} and Chiu, {Rossa W.K.} and Lo, {Keith W.K.} and Lee, {Ida P.C.} and Wong, {Raymond R.Y.} and Lau, {Kitty K.M.} and Wang, {Vivian W.} and Worley, {Michael J.} and Elias, {Kevin M.} and Fiascone, {Stephen J.} and Smith, {David I} and Berkowitz, {Ross S.} and Wong, {Yick Fu}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.ygyno.2017.05.038",
language = "English (US)",
volume = "146",
pages = "334--339",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women

AU - Chung, Tony K.H.

AU - Cheung, Tak Hong

AU - Yim, So Fan

AU - Yu, Mei Yun

AU - Chiu, Rossa W.K.

AU - Lo, Keith W.K.

AU - Lee, Ida P.C.

AU - Wong, Raymond R.Y.

AU - Lau, Kitty K.M.

AU - Wang, Vivian W.

AU - Worley, Michael J.

AU - Elias, Kevin M.

AU - Fiascone, Stephen J.

AU - Smith, David I

AU - Berkowitz, Ross S.

AU - Wong, Yick Fu

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Introduction Cervical cancer is the fourth most common female cancer worldwide. The prognosis for women with advanced-stage or recurrent cervical cancer remains poor and response to treatment is variable. Standardized management protocols leave little room for individualization. We report on a novel blood-based liquid biopsy for specific PIK3CA mutations as a clinically useful biomarker in patients with invasive cervical cancer. Methods One hundred seventeen Hong Kong Chinese women with primary invasive cervical cancer and their pre-treatment plasma samples were investigated. Two PIK3CA mutations, p.E542K and p.E545K were measured in cell free DNA (cfDNA) extracted from plasma using droplet digital PCR. This liquid biopsy of PIK3CA in cervical cancer was correlated to clinico-pathological features to verify the potential of PIK3CA as a clinically useful molecular biomarker for predicting disease prognosis and monitoring for progression. Results PIK3CA mutations, either p.E542K or p.E545K, were detected in plasma cfDNA from 22.2% of the patients. PIK3CA mutation status was significantly correlated to median tumor size (p < 0.01). PIK3CA mutations detected in the plasma were significantly associated with decreased disease-free survival and overall survival (p < 0.05). Conclusions As a liquid molecular biopsy, analysis of circulating PIK3CA mutations shows promise as a way to refine risk stratification of individual patients with cervical cancer, and provides a platform for further research to offer individualized therapy with the purpose of improving outcomes.

AB - Introduction Cervical cancer is the fourth most common female cancer worldwide. The prognosis for women with advanced-stage or recurrent cervical cancer remains poor and response to treatment is variable. Standardized management protocols leave little room for individualization. We report on a novel blood-based liquid biopsy for specific PIK3CA mutations as a clinically useful biomarker in patients with invasive cervical cancer. Methods One hundred seventeen Hong Kong Chinese women with primary invasive cervical cancer and their pre-treatment plasma samples were investigated. Two PIK3CA mutations, p.E542K and p.E545K were measured in cell free DNA (cfDNA) extracted from plasma using droplet digital PCR. This liquid biopsy of PIK3CA in cervical cancer was correlated to clinico-pathological features to verify the potential of PIK3CA as a clinically useful molecular biomarker for predicting disease prognosis and monitoring for progression. Results PIK3CA mutations, either p.E542K or p.E545K, were detected in plasma cfDNA from 22.2% of the patients. PIK3CA mutation status was significantly correlated to median tumor size (p < 0.01). PIK3CA mutations detected in the plasma were significantly associated with decreased disease-free survival and overall survival (p < 0.05). Conclusions As a liquid molecular biopsy, analysis of circulating PIK3CA mutations shows promise as a way to refine risk stratification of individual patients with cervical cancer, and provides a platform for further research to offer individualized therapy with the purpose of improving outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85020136404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020136404&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.05.038

DO - 10.1016/j.ygyno.2017.05.038

M3 - Article

C2 - 28587748

AN - SCOPUS:85020136404

VL - 146

SP - 334

EP - 339

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -